{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:18:24Z","timestamp":1787725104983,"version":"build-2784847793"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82200805"],"award-info":[{"award-number":["82200805"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Health Research Program of Anhui","award":["AHWJ2023BAc10016"],"award-info":[{"award-number":["AHWJ2023BAc10016"]}]},{"name":"Health Research Program of Anhui","award":["AHWJ2023A10010"],"award-info":[{"award-number":["AHWJ2023A10010"]}]},{"name":"Health Research Program of Anhui","award":["AHWJ2023BAc10010"],"award-info":[{"award-number":["AHWJ2023BAc10010"]}]},{"name":"the Key Project of Natural Science Research of Anhui Higher Education Institution","award":["2023AH053182"],"award-info":[{"award-number":["2023AH053182"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00898-z","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T11:54:26Z","timestamp":1741780466000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Dapagliflozin attenuates metabolic dysfunction-associated steatotic liver disease by inhibiting lipid accumulation, inflammation and liver fibrosis"],"prefix":"10.1186","volume":"26","author":[{"given":"Xingyu","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianrong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"898_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/hep.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology (Baltimore MD). 2023;77:1335\u201347. https:\/\/doi.org\/10.1097\/hep.0000000000000004.","journal-title":"Hepatology (Baltimore MD)"},{"key":"898_CR2","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jhep.2011.10.008","volume":"56","author":"J Mons\u00e9n\u00e9go","year":"2012","unstructured":"Mons\u00e9n\u00e9go J, Mansouri A, Akkaoui M, Lenoir V, Esnous C, Fauveau V, Tavernier V, Girard J, Prip-Buus C. Enhancing liver mitochondrial fatty acid oxidation capacity in obese mice improves insulin sensitivity independently of hepatic steatosis. J Hepatol. 2012;56:632\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2011.10.008.","journal-title":"J Hepatol"},{"key":"898_CR3","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","volume":"323","author":"AC Sheka","year":"2020","unstructured":"Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: A review. JAMA. 2020;323:1175\u201383. https:\/\/doi.org\/10.1001\/jama.2020.2298.","journal-title":"JAMA"},{"key":"898_CR4","doi-asserted-by":"publisher","first-page":"8591","DOI":"10.3390\/ijms15058591","volume":"15","author":"W Peverill","year":"2014","unstructured":"Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci. 2014;15:8591\u2013638. https:\/\/doi.org\/10.3390\/ijms15058591.","journal-title":"Int J Mol Sci"},{"key":"898_CR5","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/hep.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, Loomba R. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology (Baltimore MD). 2023;77:1797\u2013835. https:\/\/doi.org\/10.1097\/hep.0000000000000323.","journal-title":"Hepatology (Baltimore MD)"},{"key":"898_CR6","doi-asserted-by":"publisher","first-page":"101133","DOI":"10.1016\/j.aohep.2023.101133","volume":"29","author":"ME Rinella","year":"2024","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024;29:101133. https:\/\/doi.org\/10.1016\/j.aohep.2023.101133.","journal-title":"Ann Hepatol"},{"key":"898_CR7","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.numecd.2023.05.018","volume":"33","author":"M Wang","year":"2023","unstructured":"Wang M, Zhao Y, He Y, Zhang L, Liu J, Zheng S, Bai Y. The bidirectional relationship between NAFLD and type 2 diabetes: A prospective population-based cohort study. Nutrition, metabolism, and cardiovascular diseases. NMCD. 2023;33:1521\u20138. https:\/\/doi.org\/10.1016\/j.numecd.2023.05.018.","journal-title":"NMCD"},{"key":"898_CR8","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","volume":"70","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. 2021;70:962\u20139. https:\/\/doi.org\/10.1136\/gutjnl-2020-322572.","journal-title":"Gut"},{"key":"898_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","volume":"14","author":"H Tilg","year":"2017","unstructured":"Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14:32\u201342. https:\/\/doi.org\/10.1038\/nrgastro.2016.147.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"898_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3803\/EnM.2018.33.3.387","volume":"33","author":"DH Choi","year":"2018","unstructured":"Choi DH, Jung CH, Mok JO, Kim CH, Kang SK, Kim BY. Effect of DaPagliflozin on Alanine aminotransferase improvement in type 2 diabetes mellitus with Non-alcoholic fatty liver disease. (Seoul Korea). 2018;33:387\u201394. https:\/\/doi.org\/10.3803\/EnM.2018.33.3.387. Endocrinology and metabolism.","journal-title":"(Seoul Korea)"},{"key":"898_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/dom.13907","volume":"22","author":"A Gastaldelli","year":"2020","unstructured":"Gastaldelli A, Repetto E, Guja C, Hardy E, Han J, Jabbour SA, Ferrannini E. Exenatide and Dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. Diabetes Obes Metab. 2020;22:393\u2013403. https:\/\/doi.org\/10.1111\/dom.13907.","journal-title":"Diabetes Obes Metab"},{"key":"898_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/s1050-1738(00)00079-7","volume":"10","author":"H Shimano","year":"2000","unstructured":"Shimano H. Sterol regulatory element-binding protein-1 as a dominant transcription factor for gene regulation of lipogenic enzymes in the liver. Trends Cardiovasc Med. 2000;10:275\u20138. https:\/\/doi.org\/10.1016\/s1050-1738(00)00079-7.","journal-title":"Trends Cardiovasc Med"},{"key":"898_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/dom.13520","volume":"21","author":"M Shimizu","year":"2019","unstructured":"Shimizu M, Suzuki K, Kato K, Jojima T, Iijima T, Murohisa T, Iijima M, Takekawa H, Usui I, Hiraishi H, et al. Evaluation of the effects of Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019;21:285\u201392. https:\/\/doi.org\/10.1111\/dom.13520.","journal-title":"Diabetes Obes Metab"},{"key":"898_CR14","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2337\/dc18-1569","volume":"42","author":"A Latva-Rasku","year":"2019","unstructured":"Latva-Rasku A, Honka MJ, Kullberg J, Mononen N, Lehtim\u00e4ki T, Saltevo J, Kirjavainen AK, Saunavaara V, Iozzo P, Johansson L, et al. The SGLT2 inhibitor Dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: A randomized, Double-Blind, Placebo-Controlled study with 8-Week treatment in type 2 diabetes patients. Diabetes Care. 2019;42:931\u20137. https:\/\/doi.org\/10.2337\/dc18-1569.","journal-title":"Diabetes Care"},{"key":"898_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","volume":"45","author":"AJ Scheen","year":"2019","unstructured":"Scheen AJ. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications. Diabetes Metab. 2019;45:213\u201323. https:\/\/doi.org\/10.1016\/j.diabet.2019.01.008.","journal-title":"Diabetes Metab"},{"key":"898_CR16","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/s41591-022-01861-9","volume":"28","author":"SA Harrison","year":"2022","unstructured":"Harrison SA, Manghi FP, Smith WB, Alpenidze D, Aizenberg D, Klarenbeek N, Chen CY, Zuckerman E, Ravussin E, Charatcharoenwitthaya P, et al. Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. Nat Med. 2022;28:1432\u20138. https:\/\/doi.org\/10.1038\/s41591-022-01861-9.","journal-title":"Nat Med"},{"key":"898_CR17","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/dom.15006","volume":"25","author":"S Hiruma","year":"2023","unstructured":"Hiruma S, Shigiyama F, Kumashiro N. Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: A prospective randomized study. Diabetes Obes Metab. 2023;25:1576\u201388. https:\/\/doi.org\/10.1111\/dom.15006.","journal-title":"Diabetes Obes Metab"},{"key":"898_CR18","doi-asserted-by":"publisher","first-page":"174304","DOI":"10.1016\/j.ejphar.2021.174304","volume":"907","author":"J Luo","year":"2021","unstructured":"Luo J, Sun P, Wang Y, Chen Y, Niu Y, Ding Y, Xu N, Zhang Y, Xie W. Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK\/mTOR pathway. Eur J Pharmacol. 2021;907:174304. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174304.","journal-title":"Eur J Pharmacol"},{"key":"898_CR19","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1080\/21623945.2021.1979277","volume":"10","author":"T Han","year":"2021","unstructured":"Han T, Fan Y, Gao J, Fatima M, Zhang Y, Ding Y, Bai L, Wang C. Sodium glucose cotransporter 2 inhibitor Dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice. Adipocyte. 2021;10:446\u201355. https:\/\/doi.org\/10.1080\/21623945.2021.1979277.","journal-title":"Adipocyte"},{"key":"898_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40360-024-00747-5","volume":"25","author":"L Xiang","year":"2024","unstructured":"Xiang L, Liu M, Xiang G, Yue L, Zhang J, Xu X, Dong J. DaPagliflozin promotes white adipose tissue Browning though regulating angiogenesis in high fat induced obese mice. BMC Pharmacol Toxicol. 2024;25:26. https:\/\/doi.org\/10.1186\/s40360-024-00747-5.","journal-title":"BMC Pharmacol Toxicol"},{"key":"898_CR21","doi-asserted-by":"publisher","first-page":"e1098","DOI":"10.1002\/jsp2.1098","volume":"3","author":"A Binch","year":"2020","unstructured":"Binch A, Snuggs J, Le Maitre CL. Immunohistochemical analysis of protein expression in formalin fixed paraffin embedded human intervertebral disc tissues. JOR Spine. 2020;3:e1098. https:\/\/doi.org\/10.1002\/jsp2.1098.","journal-title":"JOR Spine"},{"key":"898_CR22","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/s2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, Swain MG, Congly SE, Kaplan GG, Shaheen AA. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851\u201361. https:\/\/doi.org\/10.1016\/s2468-1253(22)00165-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"898_CR23","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/apt.18377","volume":"61","author":"M Amangurbanova","year":"2025","unstructured":"Amangurbanova M, Huang DQ, Noureddin N, Tesfai K, Bettencourt R, Siddiqi H, Lopez SJ, Cervantes V, Madamba E, Loomba R. A prospective study on the prevalence of MASLD in patients with type 2 diabetes and hyperferritinaemia. Aliment Pharmacol Ther. 2025;61:456\u201364. https:\/\/doi.org\/10.1111\/apt.18377.","journal-title":"Aliment Pharmacol Ther"},{"key":"898_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s12916-023-03129-6","volume":"21","author":"M Deng","year":"2023","unstructured":"Deng M, Wen Y, Yan J, Fan Y, Wang Z, Zhang R, Ren L, Ba Y, Wang H, Lu Q, et al. Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and bayesian network meta-analysis of randomised controlled trials. BMC Med. 2023;21:447. https:\/\/doi.org\/10.1186\/s12916-023-03129-6.","journal-title":"BMC Med"},{"key":"898_CR25","doi-asserted-by":"publisher","unstructured":"Lee JY, An M, Heo H, Park JY, Lee J, Kang CH. Limosilactobacillus fermentum MG4294 and Lactiplantibacillus plantarum MG5289 ameliorates nonalcoholic fatty liver disease in High-Fat Diet-Induced mice. Nutrients. 2023;15. https:\/\/doi.org\/10.3390\/nu15082005.","DOI":"10.3390\/nu15082005"},{"key":"898_CR26","doi-asserted-by":"publisher","first-page":"e6796","DOI":"10.1371\/journal.pone.0006796","volume":"4","author":"M Rakhshandehroo","year":"2009","unstructured":"Rakhshandehroo M, Hooiveld G, M\u00fcller M, Kersten S. Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS ONE. 2009;4:e6796. https:\/\/doi.org\/10.1371\/journal.pone.0006796.","journal-title":"PLoS ONE"},{"key":"898_CR27","doi-asserted-by":"publisher","unstructured":"Androutsakos T, Nasiri-Ansari N, Bakasis AD, Kyrou I, Efstathopoulos E, Randeva HS, Kassi E. SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection. Int J Mol Sci. 2022;23. https:\/\/doi.org\/10.3390\/ijms23063107.","DOI":"10.3390\/ijms23063107"},{"key":"898_CR28","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","volume":"77","author":"M Peiseler","year":"2022","unstructured":"Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenw\u00e4lder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol. 2022;77:1136\u201360. https:\/\/doi.org\/10.1016\/j.jhep.2022.06.012.","journal-title":"J Hepatol"},{"key":"898_CR29","doi-asserted-by":"publisher","first-page":"880298","DOI":"10.3389\/fimmu.2022.880298","volume":"13","author":"Y Duan","year":"2022","unstructured":"Duan Y, Pan X, Luo J, Xiao X, Li J, Bestman PL, Luo M. Association of inflammatory cytokines with Non-Alcoholic fatty liver disease. Front Immunol. 2022;13:880298. https:\/\/doi.org\/10.3389\/fimmu.2022.880298.","journal-title":"Front Immunol"},{"key":"898_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12967-019-1881-8","volume":"17","author":"AA Sayour","year":"2019","unstructured":"Sayour AA, Korkmaz-Ic\u00f6z S, Loganathan S, Ruppert M, Sayour VN, Ol\u00e1h A, Benke K, Brune M, Benk\u0151 R, Horv\u00e1th EM, et al. Acute Canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation. J Translational Med. 2019;17:127. https:\/\/doi.org\/10.1186\/s12967-019-1881-8.","journal-title":"J Translational Med"},{"key":"898_CR31","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","volume":"715","author":"A Tahara","year":"2013","unstructured":"Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, et al. Effects of SGLT2 selective inhibitor Ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013;715:246\u201355. https:\/\/doi.org\/10.1016\/j.ejphar.2013.05.014.","journal-title":"Eur J Pharmacol"},{"key":"898_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13098-024-01325-9","volume":"16","author":"R Zhang","year":"2024","unstructured":"Zhang R, Xie Q, Lu X, Fan R, Tong N. Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus. Diabetol Metab Syndr. 2024;16:99. https:\/\/doi.org\/10.1186\/s13098-024-01325-9.","journal-title":"Diabetol Metab Syndr"},{"key":"898_CR33","doi-asserted-by":"publisher","first-page":"597648","DOI":"10.3389\/fendo.2020.597648","volume":"11","author":"C Luci","year":"2020","unstructured":"Luci C, Bourinet M, Lecl\u00e8re PS, Anty R, Gual P. Chronic inflammation in Non-Alcoholic steatohepatitis: molecular mechanisms and therapeutic strategies. Front Endocrinol. 2020;11:597648. https:\/\/doi.org\/10.3389\/fendo.2020.597648.","journal-title":"Front Endocrinol"},{"key":"898_CR34","doi-asserted-by":"publisher","unstructured":"Gensluckner S, Wernly B, Datz C, Aigner E. Iron, oxidative stress, and metabolic Dysfunction-Associated steatotic liver disease. Antioxid (Basel Switzerland). 2024;13. https:\/\/doi.org\/10.3390\/antiox13020208.","DOI":"10.3390\/antiox13020208"},{"key":"898_CR35","doi-asserted-by":"publisher","unstructured":"Pruett JE, Everman SJ, Hoang NH, Salau F, Taylor LC, Edwards KS, Hosler JP, Huffman AM, Romero DG, Yanes Cardozo LL. Mitochondrial function and oxidative stress in white adipose tissue in a rat model of PCOS: effect of SGLT2 Inhibition. Biology Sex Differences. 2022;13(45). https:\/\/doi.org\/10.1186\/s13293-022-00455-x.","DOI":"10.1186\/s13293-022-00455-x"},{"key":"898_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.freeradbiomed.2024.01.015","volume":"213","author":"C Luna-Marco","year":"2024","unstructured":"Luna-Marco C, Iannantuoni F, Hermo-Argibay A, Devos D, Salazar JD, V\u00edctor VM, Rovira-Llopis S. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress. Free Radic Biol Med. 2024;213:19\u201335. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2024.01.015.","journal-title":"Free Radic Biol Med"},{"key":"898_CR37","doi-asserted-by":"publisher","first-page":"429","DOI":"10.21037\/atm.2019.09.03","volume":"7","author":"W Leng","year":"2019","unstructured":"Leng W, Wu M, Pan H, Lei X, Chen L, Wu Q, Ouyang X, Liang Z. The SGLT2 inhibitor Dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus. Annals Translational Med. 2019;7:429. https:\/\/doi.org\/10.21037\/atm.2019.09.03.","journal-title":"Annals Translational Med"},{"key":"898_CR38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3350\/cmh.2022.0237","volume":"29","author":"KC Lee","year":"2023","unstructured":"Lee KC, Wu PS, Lin HC. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. Clin Mol Hepatol. 2023;29:77\u201398. https:\/\/doi.org\/10.3350\/cmh.2022.0237.","journal-title":"Clin Mol Hepatol"},{"key":"898_CR39","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14:397\u2013411. https:\/\/doi.org\/10.1038\/nrgastro.2017.38.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"898_CR40","doi-asserted-by":"publisher","unstructured":"Heo YJ, Lee N, Choi SE, Jeon JY, Han SJ, Kim DJ, Kang Y, Lee KW, Kim HJ. Empagliflozin reduces the progression of hepatic fibrosis in a mouse model and inhibits the activation of hepatic stellate cells via the Hippo signalling pathway. Biomedicines. 2022;10. https:\/\/doi.org\/10.3390\/biomedicines10051032.","DOI":"10.3390\/biomedicines10051032"},{"key":"898_CR41","doi-asserted-by":"publisher","first-page":"155657","DOI":"10.1016\/j.metabol.2023.155657","volume":"146","author":"Y Shen","year":"2023","unstructured":"Shen Y, Cheng L, Xu M, Wang W, Wan Z, Xiong H, Guo W, Cai M, Xu F. SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis. Metab Clin Exp. 2023;146:155657. https:\/\/doi.org\/10.1016\/j.metabol.2023.155657.","journal-title":"Metab Clin Exp"},{"key":"898_CR42","doi-asserted-by":"publisher","first-page":"1144838","DOI":"10.3389\/fendo.2023.1144838","volume":"14","author":"P Zhou","year":"2023","unstructured":"Zhou P, Tan Y, Hao Z, Xu W, Zhou X, Yu J. Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis. Front Endocrinol. 2023;14:1144838. https:\/\/doi.org\/10.3389\/fendo.2023.1144838.","journal-title":"Front Endocrinol"},{"key":"898_CR43","doi-asserted-by":"publisher","first-page":"155835","DOI":"10.1016\/j.metabol.2024.155835","volume":"154","author":"M Kokkorakis","year":"2024","unstructured":"Kokkorakis M, Boutari C, Hill MA, Kotsis V, Loomba R, Sanyal AJ, Mantzoros CS. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges. Metab Clin Exp. 2024;154:155835. https:\/\/doi.org\/10.1016\/j.metabol.2024.155835.","journal-title":"Metab Clin Exp"},{"key":"898_CR44","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s2468-1253(24)00049-9","volume":"9","author":"H. The Lancet Gastroenterology","year":"2024","unstructured":"H. The Lancet Gastroenterology. Resmetirom for NASH: balancing promise and Prudence. The lancet. Gastroenterol Hepatol. 2024;9:273. https:\/\/doi.org\/10.1016\/s2468-1253(24)00049-9.","journal-title":"Gastroenterol Hepatol"},{"key":"898_CR45","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1056\/NEJMe2314365","volume":"390","author":"K Cusi","year":"2024","unstructured":"Cusi K. Selective agonists of thyroid hormone receptor Beta for the treatment of NASH. N Engl J Med. 2024;390:559\u201361. https:\/\/doi.org\/10.1056\/NEJMe2314365.","journal-title":"N Engl J Med"},{"key":"898_CR46","doi-asserted-by":"publisher","unstructured":"Mantovani A, Petracca G, Csermely A, Beatrice G, Targher G. Sodium-Glucose Cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: A Meta-Analysis of randomized controlled trials. Metabolites. 2020;11. https:\/\/doi.org\/10.3390\/metabo11010022.","DOI":"10.3390\/metabo11010022"},{"key":"898_CR47","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1002\/hep4.2069","volume":"6","author":"T Arai","year":"2022","unstructured":"Arai T, Atsukawa M, Tsubota A, Mikami S, Haruki U, Yoshikata K, Ono H, Kawano T, Yoshida Y, Tanabe T, et al. Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus. Hepatol Commun. 2022;6:3073\u201382. https:\/\/doi.org\/10.1002\/hep4.2069.","journal-title":"Hepatol Commun"},{"key":"898_CR48","doi-asserted-by":"publisher","first-page":"F653","DOI":"10.1152\/ajprenal.00143.2018","volume":"315","author":"T Masuda","year":"2018","unstructured":"Masuda T, Watanabe Y, Fukuda K, Watanabe M, Onishi A, Ohara K, Imai T, Koepsell H, Muto S, Vallon V, et al. Unmasking a sustained negative effect of SGLT2 Inhibition on body fluid volume in the rat. American journal of physiology. Ren Physiol. 2018;315:F653\u201364. https:\/\/doi.org\/10.1152\/ajprenal.00143.2018.","journal-title":"Ren Physiol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00898-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00898-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00898-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T20:58:21Z","timestamp":1741813101000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00898-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["898"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00898-z","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"15 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Animal Experimental and Ethics Committee of the Second Affiliated Hospital of Anhui Medical University and performed in compliance with the guidelines of the Committee of Animal Care and Use of the Second Affiliated Hospital of Anhui Medical University and ARRIVE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}